{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:56:00Z","timestamp":1792068960555,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.7759\/cureus.117968","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:42:44Z","timestamp":1792068164000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Ritlecitinib, Baricitinib, and Upadacitinib in Adolescents With Severe Alopecia Areata: A Bayesian Network Meta\u2011Analysis"],"prefix":"10.7759","author":[{"given":"Arya","family":"Babul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devina","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yssra","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rajpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15842","article-title":"Pathophysiology of alopecia areata in the pediatric patient","volume":"42","author":"Fitzhugh MH","year":"2025","unstructured":"Fitzhugh MH, Hansen JG, Jabbari A, Berrebi KG. Pathophysiology of alopecia areata in the pediatric patient. Pediatr Dermatol. 2025, 42:24-30. 10.1111\/pde.15842","journal-title":"Pediatr Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.16678","article-title":"Psychosocial impact of alopecia areata in paediatric and adolescent populations: a systematic review","volume":"60","author":"Tan IJ","year":"2024","unstructured":"Tan IJ, Jafferany M. Psychosocial impact of alopecia areata in paediatric and adolescent populations: a systematic review. J Paediatr Child Health. 2024, 60:778-82. 10.1111\/jpc.16678","journal-title":"J Paediatr Child Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijt.ijt_28_21","article-title":"An updated review on current treatment of alopecia areata and newer therapeutic options","volume":"15","author":"Malhotra K","year":"2023","unstructured":"Malhotra K, Madke B. An updated review on current treatment of alopecia areata and newer therapeutic options. Int J Trichology. 2023, 15:3-12. 10.4103\/ijt.ijt_28_21","journal-title":"Int J Trichology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.11.070","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial","volume":"94","author":"Tsianakas A","year":"2026","unstructured":"Tsianakas A, Passeron T, Magnolo N, et al.. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2026, 94:1134-43. 10.1016\/j.jaad.2025.11.070","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17442","article-title":"Efficacy and safety of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis","volume":"51","author":"Mesinkovska N","year":"2024","unstructured":"Mesinkovska N, King B, Zhang X, et al.. Efficacy and safety of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. J Dermatol. 2024, 51:1414-24. 10.1111\/1346-8138.17442","journal-title":"J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.12.008","article-title":"Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial","volume":"87","author":"Peeva E","year":"2022","unstructured":"Peeva E, Guttman-Yassky E, Banerjee A, et al.. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. J Am Acad Dermatol. 2022, 87:390-3. 10.1016\/j.jaad.2021.12.008","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2734","article-title":"Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial","volume":"160","author":"King B","year":"2024","unstructured":"King B, Ko J, Kwon O, et al.. Baricitinib withdrawal and retreatment in patients with severe alopecia areata: the BRAVE-AA1 randomized clinical trial. JAMA Dermatol. 2024, 160:1075-81. 10.1001\/jamadermatol.2024.2734","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King B","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et al.. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024, 91:880-8. 10.1016\/j.jaad.2024.06.097","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae365","article-title":"Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata","volume":"192","author":"Piliang M","year":"2025","unstructured":"Piliang M, Soung J, King B, et al.. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24\u2005months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025, 192:215-27. 10.1093\/bjd\/ljae365","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon O","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, et al.. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023, 24:443-51. 10.1007\/s40257-023-00764-w","journal-title":"Am J Clin Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King B","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al.. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022, 386:1687-99. 10.1056\/NEJMoa2110343","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15378","article-title":"Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial","volume":"40","author":"Hordinsky M","year":"2023","unstructured":"Hordinsky M, Hebert AA, Gooderham M, et al.. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023, 40:1003-9. 10.1111\/pde.15378","journal-title":"Pediatr Dermatol"},{"key":"ref13","unstructured":"Leqselvi (deuruxolitinib) US Prescribing Information, 06\/30\/2026 (SUPPL-2), NDA 217900, Sun Pharmaceuticals. (2026). Accessed. September 28, 2026: https:\/\/tinyurl.com\/y7tw7xvf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King B","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al.. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023, 401:1518-29. 10.1016\/S0140-6736(23)00222-2","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1766847","article-title":"Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review","volume":"17","author":"Wan Z","year":"2026","unstructured":"Wan Z, Wang Y, Yang D. Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review. Front Immunol. 2026, 17:1766847. 10.3389\/fimmu.2026.1766847","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.70123","article-title":"Ritlecitinib in alopecia areata: a 24-week real-world experience contrasting JAK inhibitor-na\u00efve and JAK inhibitor-experienced patients","volume":"53","author":"Okazaki T","year":"2026","unstructured":"Okazaki T, Takahashi T, Wada-Irimada M, et al.. Ritlecitinib in alopecia areata: a 24-week real-world experience contrasting JAK inhibitor-na\u00efve and JAK inhibitor-experienced patients. J Dermatol. 2026, 53:470-7. 10.1111\/1346-8138.70123","journal-title":"J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15062","article-title":"Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata","volume":"34","author":"Peterson D","year":"2021","unstructured":"Peterson D, Powell M, King B. Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata. Dermatol Ther. 2021, 34:e15062. 10.1111\/dth.15062","journal-title":"Dermatol Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.3537","article-title":"Successful treatment of alopecia areata with one JAK inhibitor after failure of other JAK inhibitors","volume":"161","author":"Kalil L","year":"2025","unstructured":"Kalil L, Craiglow BG, King B. Successful treatment of alopecia areata with one JAK inhibitor after failure of other JAK inhibitors. JAMA Dermatol. 2025, 161:1285-7. 10.1001\/jamadermatol.2025.3537","journal-title":"JAMA Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00884-x","article-title":"Predictors and management of inadequate response to JAK inhibitors in alopecia areata","volume":"25","author":"Zhang X","year":"2024","unstructured":"Zhang X, Jiang Y. Predictors and management of inadequate response to JAK inhibitors in alopecia areata. Am J Clin Dermatol. 2024, 25:975-86. 10.1007\/s40257-024-00884-x","journal-title":"Am J Clin Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-03848-1","article-title":"Jak inhibitor intraclass switch in alopecia areata patients: a retrospective review of cases at an academic center","volume":"317","author":"Silva I","year":"2025","unstructured":"Silva I, Khattri S. Jak inhibitor intraclass switch in alopecia areata patients: a retrospective review of cases at an academic center. Arch Dermatol Res. 2025, 317:411. 10.1007\/s00403-025-03848-1","journal-title":"Arch Dermatol Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.055","article-title":"Switching between Janus kinase inhibitors for treatment of alopecia areata: a multicenter retrospective review","volume":"94","author":"Martin A","year":"2026","unstructured":"Martin A, Chen LC, Kreytak C, et al.. Switching between Janus kinase inhibitors for treatment of alopecia areata: a multicenter retrospective review. J Am Acad Dermatol. 2026, 94:1662-70. 10.1016\/j.jaad.2026.01.055","journal-title":"J Am Acad Dermatol"},{"key":"ref22","unstructured":"Olumiant (baricitinib) US Prescribing Information, 06\/30\/2026 (SUPPL-11), NDA 207924, Eli Lilly & Co. (2026). Accessed. September 28, 2026: https:\/\/tinyurl.com\/muwx3jd7."},{"key":"ref23","unstructured":"Litfulo (Ritlecitinib) US Prescribing Information, 06\/30\/2026 (SUPPL-1), NDA 215830, Pfizer. (2023). Accessed. September 28, 2026: https:\/\/tinyurl.com\/3kpur4de."},{"key":"ref24","unstructured":"Olumiant (Baricitinib) Summary of Product Characteristics. (2026). Accessed. September 28, 2026: https:\/\/tinyurl.com\/9de3p56r."},{"key":"ref25","unstructured":"Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata, press release, Feb 27. (2026). Accessed. September 28, 2026: https:\/\/tinyurl.com\/2apn3m33."},{"key":"ref26","unstructured":"AbbVie submits application to FDA for upadacitinib (RINVOQ) for adults and adolescents with severe alopecia areata. (2026). Accessed. September 28, 2026: https:\/\/tinyurl.com\/dhtxy8ud."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the treatment of alopecia areata","volume":"83","author":"Freitas E","year":"2023","unstructured":"Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023, 83:761-70. 10.1007\/s40265-023-01873-w","journal-title":"Drugs"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.2012149","article-title":"Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata","volume":"30","author":"Eisman S","year":"2021","unstructured":"Eisman S, Sinclair R. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata. Expert Opin Investig Drugs. 2021, 30:1169-74. 10.1080\/13543784.2021.2012149","journal-title":"Expert Opin Investig Drugs"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.3390\/dermato6020019","article-title":"Ritlecitinib for the management of alopecia areata: a narrative review of real-world evidence and selected post hoc analyses","volume":"6","author":"Lauletta G","year":"2026","unstructured":"Lauletta G, Potestio L, Nappa P, Napolitano M. Ritlecitinib for the management of alopecia areata: a narrative review of real-world evidence and selected post hoc analyses. Dermato. 2026, 6:19.","journal-title":"Dermato"},{"key":"ref30","unstructured":"Rinvoq (upadacitinib), US Prescribing Information, 06\/30\/2026 (SUPPL-34), NDA 211675, Abbvie. (2026). Accessed. September 28, 2026: https:\/\/tinyurl.com\/3ww9jw6r."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.2853","article-title":"Upadacitinib for severe alopecia areata in adults and adolescents: two phase 3 UP-AA randomized clinical trials","author":"Mostaghimi A","year":"2026","unstructured":"Mostaghimi A, Gooderham MJ, Lynde C, et al.. Upadacitinib for severe alopecia areata in adults and adolescents: two phase 3 UP-AA randomized clinical trials. JAMA Dermatol. 2026, 10.1001\/jamadermatol.2026.2853","journal-title":"JAMA Dermatol"},{"key":"ref32","unstructured":"Upadacitinib (Rinvoq), Summary of Product Characteristics, European Medicines Agency, AbbVie Deutschland GmbH. (2026). Accessed. September 28, 2026: https:\/\/tinyurl.com\/mrxurshw."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.382","article-title":"Treatment patterns of patients with Alopecia areata treated with FDA-approved JAK inhibitors (AB95)","volume":"93","author":"Mostaghimi A","year":"2025","unstructured":"Mostaghimi A, Senna MM, Huynh L, et al.. Treatment patterns of patients with Alopecia areata treated with FDA-approved JAK inhibitors (AB95). J Am Acad Dermatol. 2025, 93:3. 10.1016\/j.jaad.2025.05.382","journal-title":"J Am Acad Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2022.2115965","article-title":"A gentle introduction to Bayesian network meta-analysis using an automated R package","volume":"58","author":"Liu Y","year":"2023","unstructured":"Liu Y, B\u00e9liveau A, Wei Y, et al.. A gentle introduction to Bayesian network meta-analysis using an automated R package. Multivariate Behav Res. 2023, 58:706-22. 10.1080\/00273171.2022.2115965","journal-title":"Multivariate Behav Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2016.02.025","article-title":"The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA","volume":"147","author":"Hutton B","year":"2016","unstructured":"Hutton B, Catal\u00e1-L\u00f3pez F, Moher D. The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Med Clin. 2016, 147:262-6. 10.1016\/j.medcli.2016.02.025","journal-title":"Med Clin"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.108824","article-title":"Epistemic barriers to buprenorphine access for adolescents with opioid use disorder","volume":"18","author":"Babul A","year":"2026","unstructured":"Babul A, Ashraf S, Elmes R, Mahdavi P. Epistemic barriers to buprenorphine access for adolescents with opioid use disorder. Cureus. 2026, 18:e108824. 10.7759\/cureus.108824","journal-title":"Cureus"},{"key":"ref37","unstructured":"Drug Approval Package. Litfulo, Pfizer, Inc., Approval Date: 6\/23\/2023. Center For Drug Evaluation and Research, Food and Drug Administration. Application Number: 215830Orig1s000 Multi-Discipline Review. (2023). Accessed: September 28, 2026: https:\/\/tinyurl.com\/ybanzdra."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2020.61.564","article-title":"Bayesian meta-analysis now - let's do it","volume":"61","author":"Hackenberger BK","year":"2020","unstructured":"Hackenberger BK. Bayesian meta-analysis now - let's do it. Croat Med J. 2020, 61:564-8. 10.3325\/cmj.2020.61.564","journal-title":"Croat Med J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref40","article-title":"Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a phase 3 randomized, controlled trial","volume":"24","author":"Passeron T","year":"2026","unstructured":"Passeron T, Arkin L, Ohyama M, et al.. Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a phase 3 randomized, controlled trial. J Dtsch Dermatol Ges. 2026, 24:","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata","volume":"13","author":"Lensing M","year":"2022","unstructured":"Lensing M, Jabbari A. An overview of JAK\/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022, 13:10.3389\/fimmu.2022.955035","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2348062","article-title":"Novel investigational drugs for alopecia areata and future perspectives","volume":"33","author":"Chim I","year":"2024","unstructured":"Chim I, Ghiya R, Sinclair RD, Eisman S. Novel investigational drugs for alopecia areata and future perspectives. Expert Opin Investig Drugs. 2024, 33:441-9. 10.1080\/13543784.2024.2348062","journal-title":"Expert Opin Investig Drugs"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01543-7","article-title":"Rationale and design of a novel, phase 3, external and synthetic placebo-controlled clinical trial of ritlecitinib 50 mg and 100 mg for alopecia areata","volume":"15","author":"King B","year":"2025","unstructured":"King B, McMichael A, Sinclair R, et al.. Rationale and design of a novel, phase 3, external and synthetic placebo-controlled clinical trial of ritlecitinib 50 mg and 100 mg for alopecia areata. Dermatol Ther. 2025, 15:3793-803. 10.1007\/s13555-025-01543-7","journal-title":"Dermatol Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.087","article-title":"Evaluating dermatologists' knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata","volume":"91","author":"Nohria A","year":"2024","unstructured":"Nohria A, Desai D, Lee A, Karagounis T, Shapiro J, Garshick M, Lo Sicco KI. Evaluating dermatologists' knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata. J Am Acad Dermatol. 2024, 91:976-8. 10.1016\/j.jaad.2024.06.087","journal-title":"J Am Acad Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00805-4","article-title":"Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis","volume":"24","author":"Ly S","year":"2023","unstructured":"Ly S, Manjaly P, Kamal K, et al.. Comorbid conditions associated with alopecia areata: a systematic review and meta-analysis. Am J Clin Dermatol. 2023, 24:875-93. 10.1007\/s40257-023-00805-4","journal-title":"Am J Clin Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdrv.2025.08.006","article-title":"Alopecia areata: a clinical review of the changing landscape with Janus kinase inhibitors","volume":"7","author":"Lebwohl MG","year":"2026","unstructured":"Lebwohl MG, Lain EL, McMichael A, Senna MM, Mesinkovska NA. Alopecia areata: a clinical review of the changing landscape with Janus kinase inhibitors. JAAD Rev. 2026, 7:1-8. 10.1016\/j.jdrv.2025.08.006","journal-title":"JAAD Rev"},{"key":"ref47","unstructured":"Nektar Therapeutics. REZOLVE-A phase 2b study of rezpegaldesleukin establishes proof-of-concept in patients with severe-to-very-severe alopecia areata. (2025). Accessed: September 28, 2026: https:\/\/tinyurl.com\/22vsr3z8."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/538885-comparative-efficacy-of-ritlecitinib-baricitinib-and-upadacitinib-in-adolescents-with-severe-alopecia-areata-a-bayesian-network-metaanalysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:42:46Z","timestamp":1792068166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/538885-comparative-efficacy-of-ritlecitinib-baricitinib-and-upadacitinib-in-adolescents-with-severe-alopecia-areata-a-bayesian-network-metaanalysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.117968","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}